6533b82dfe1ef96bd129134d
RESEARCH PRODUCT
In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin- and N-pyrazin-2-ylbenzenesulfonamides, and N2-(4-nitrophenyl)-N1-propylglycinamide.
Encarna CastilloJoaquín BorrásM. Eugenia González-rosendeM. Auxiliadora Dea-ayuelaM. Auxiliadora Dea-ayuelaCeleste VegaMarta González-álvarezMarta González-álvarezFrancisco Bolás-fernándezMiriam Soledad Rolónsubject
StereochemistryClinical BiochemistryNitro compoundGlycinePharmaceutical ScienceBiochemistryChemical synthesisMiceIn vivoDrug DiscoverymedicineAnimalsMolecular BiologyLeishmaniasischemistry.chemical_classificationNucleaseMice Inbred BALB CSulfonamidesAniline CompoundsbiologyOrganic Chemistrybiology.organism_classificationTrypanocidal AgentsIn vitroPyrimidineschemistryMechanism of actionBiochemistrybiology.proteinNitroMolecular MedicineLeishmania infantummedicine.symptomdescription
A series of compounds containing the nitrobenzene and sulfonamido moieties were synthesized and their leishmanicidal effect was assessed in vitro against Leishmania infantum promastigotes. Among the compounds evaluated, the p-nitrobenzenesulfonamides 4Aa and 4Ba, and the p-nitroaniline 5 showed significant activity with a good selectivity index. In a Balb/c mice model of L. Infantum, administration of compounds 4Aa, 4Ba or 5 (5 mg/kg/day for 10 days, injected ip route) led to a clear-cut parasite burden reduction (ca. 99%). In an attempt to elucidate their mechanism of action, the DNA interaction of 4Aa and 5 was investigated by means of viscosity studies, thermal denaturation and nuclease activity assay. Both compounds showed nuclease activity in the presence of copper salt. The results suggest that compounds 4Aa, 4Ba and 5 represent possible candidates for drug development in the therapeutic control of leishmaniasis.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2009-11-01 | Bioorganicmedicinal chemistry |